O'Connor DT - Search Results

1

Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure.

Ziegler MG, Kennedy B, Morrissey E, O'Connor DT. Ziegler MG, et al. Kidney Int. 1990 May;37(5):1357-62. doi: 10.1038/ki.1990.122. Kidney Int. 1990. PMID: 2345431 Free article.

2

Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits.

Fung MM, Rana BK, Tang CM, Shiina T, Nievergelt CM, Rao F, Salem RM, Waalen J, Ziegler MG, Insel PA, O'Connor DT. Fung MM, et al. Kidney Int. 2009 Nov;76(10):1070-80. doi: 10.1038/ki.2009.306. Epub 2009 Aug 12. Kidney Int. 2009. PMID: 19675531 Free PMC article.

3

Does chromogranin a respond to short-term mild physiologic challenge?

Dimsdale JE, O'Connor D, Ziegler M, Mills P. Dimsdale JE, et al. Neuropsychopharmacology. 1989 Sep;2(3):237-40. doi: 10.1016/0893-133x(89)90027-4. Neuropsychopharmacology. 1989. PMID: 2789663

4

Plasma norepinephrine kinetics, dopamine-beta-hydroxylase, and chromogranin-A, in hypothyroid patients before and following replacement therapy.

Polikar R, Kennedy B, Ziegler M, O'Connor DT, Smith J, Nicod P. Polikar R, et al. J Clin Endocrinol Metab. 1990 Jan;70(1):277-81. doi: 10.1210/jcem-70-1-277. J Clin Endocrinol Metab. 1990. PMID: 2294136

5

Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo.

Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Kennedy BP, et al. Peptides. 1998;19(7):1241-8. doi: 10.1016/s0196-9781(98)00086-2. Peptides. 1998. PMID: 9786174

6

Ultradian variations of chromogranin A in humans.

Takiyyuddin MA, Neumann HP, Cervenka JH, Kennedy B, Dinh TQ, Ziegler MG, Baron AD, O'Connor DT. Takiyyuddin MA, et al. Am J Physiol. 1991 Oct;261(4 Pt 2):R939-44. doi: 10.1152/ajpregu.1991.261.4.R939. Am J Physiol. 1991. PMID: 1681748

7

Chromogranin A correlates with norepinephrine release rate.

Dimsdale JE, O'Connor DT, Ziegler M, Mills P. Dimsdale JE, et al. Life Sci. 1992;51(7):519-25. doi: 10.1016/0024-3205(92)90029-o. Life Sci. 1992. PMID: 1640800

8

Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Chen Y, Rao F, Rodriguez-Flores JL, Mahapatra NR, Mahata M, Wen G, Salem RM, Shih PA, Das M, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, O'Connor DT. Chen Y, et al. Kidney Int. 2008 Jul;74(1):115-25. doi: 10.1038/ki.2008.113. Epub 2008 Apr 23. Kidney Int. 2008. PMID: 18432188 Free PMC article.

9

The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension.

O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. O'Connor DT, et al. Ann N Y Acad Sci. 2002 Oct;971:533-5. doi: 10.1111/j.1749-6632.2002.tb04520.x. Ann N Y Acad Sci. 2002. PMID: 12438176 No abstract available.

10

Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.

Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT. Mahata SK, et al. J Biol Chem. 2003 Aug 22;278(34):32058-67. doi: 10.1074/jbc.M305545200. Epub 2003 Jun 10. J Biol Chem. 2003. PMID: 12799369 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

419 results

Search Page

Filters